SRZN Stock Price, Surrozen, Inc. Quote, Chart

Market Summary

USD9.58-0.57

Delayedas of 17 May 2024, 01:01 pm

-5.62%

SRZN Alerts

2 major insider buys recently.

SRZN Stock Price

View Fullscreen

SRZN RSI Chart

SRZN Valuation

Market Cap

32.5M

Price/Earnings (Trailing)

-0.86

Price/Sales (Trailing)

2.61

Price/Free Cashflow

-0.93

SRZN Price/Sales (Trailing)

SRZN Profitability

Return on Equity

-124.68%

Return on Assets

-102.34%

Free Cashflow Yield

-107.89%

SRZN Fundamentals

SRZN Revenue

Revenue (TTM)

12.5M

SRZN Earnings

Earnings (TTM)

-37.6M

Earnings Growth (Yr)

38.24%

Earnings Growth (Qtr)

0.93%

Breaking Down SRZN Revenue

52 Week Range

0.439.94

(Low)(High)

Last 7 days

-0.8%

Last 30 days

8.9%

Last 90 days

-14.6%

Trailing 12 Months

1745.5%

How does SRZN drawdown profile look like?

SRZN Financial Health

Current Ratio

5.18

SRZN Investor Care

Buy Backs (1Y)

12.95%

Diluted EPS (TTM)

-35.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	0	0	0	12.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Surrozen, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 04, 2024	column group iii gp, lp	bought	1,591,090	15.5	102,651	-
Apr 04, 2024	column group iii gp, lp	bought	1,408,900	15.5	90,897	-
Apr 04, 2024	kutzkey tim	bought	1,591,090	15.5	102,651	-
Apr 04, 2024	kutzkey tim	bought	1,408,900	15.5	90,897	-
Apr 04, 2024	parker craig c	bought	-	-	1,474	chief executive officer
Apr 04, 2024	williams charles o	bought	-	-	1,474	cfo and coo

Which funds bought or sold SRZN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	unchanged	-	222,181	553,164	-%
May 15, 2024	Royal Bank of Canada	added	42.34	1,000	2,000	-%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	unchanged	-	1,800	5,033	-%
May 15, 2024	CANTOR FITZGERALD, L. P.	unchanged	-	725	1,408	-%
May 15, 2024	BRIDGER MANAGEMENT, LLC	unchanged	-	5,040	14,093	0.01%
May 15, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	1,700	5,033	-%
May 15, 2024	BAKER BROS. ADVISORS LP	unchanged	-	9,000	25,167	-%
May 15, 2024	Board of Trustees of The Leland Stanford Junior University	reduced	-	328,933	818,962	0.07%
May 15, 2024	PRELUDE CAPITAL MANAGEMENT, LLC	unchanged	-	265	743	-%
May 15, 2024	Alyeska Investment Group, L.P.	unchanged	-	128,573	320,107	-%

Are Funds Buying or Selling SRZN?

Are funds buying SRZN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SRZN

No. of Funds

SRZN Alerts

2 major insider buys recently.

Unveiling Surrozen, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 19, 2024	stonepine capital management, llc	6.0%	199,158	SC 13G
Apr 17, 2024	column group iii gp, lp	33.9%	1,225,273	SC 13D/A
Apr 15, 2024	ra capital management, l.p.	9.99%	323,662	SC 13G
Apr 08, 2024	column group iii gp, lp	34.2%	1,236,384	SC 13D/A
Feb 14, 2024	alyeska investment group, l.p.	9.99%	203,629	SC 13G
Feb 09, 2024	goldman sachs group inc	7.9%	172,666	SC 13G
Feb 07, 2024	bml investment partners, l.p.	0.0%	0	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	2.3%	833,333	SC 13G/A
Feb 13, 2023	column group iii gp, lp	31.5%	9,414,795	SC 13D/A
Feb 02, 2023	regents of the university of california	5.93%	2,081,453	SC 13G/A

Recent SEC filings of Surrozen, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 25, 2024	EFFECT	EFFECT
Apr 25, 2024	424B5	Prospectus Filed

Peers (Alternatives to Surrozen, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Surrozen, Inc. News

Latest updates

Surrozen, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)		(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4
Operating Expenses	-33.7%	10.00	15.00
S&GA Expenses	-31.4%	4.00	5.00
R&D Expenses	-35.4%	6.00	9.00
Net Income	-1089.2%	-8.91	-0.75
Net Income Margin	-19.5%	-3.44*	-2.88*
Free Cashflow	-1987.1%	-7.26	-0.35

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-20.3%	37.00	46.00	54.00	64.00	74.00	89.00	91.00	104	118	137	151	93.00	93.00	62.00	52.00	42.00
Current Assets	-22.2%	32.00	41.00	48.00	58.00	67.00	81.00	83.00	95.00	96.00	105	114	1.00	1.00	50.00	-	29.00
Cash Equivalents	-22.4%	28.00	36.00	34.00	36.00	28.00	25.00	26.00	17.00	14.00	33.00	61.00	19.00	23.00	35.00	59.00	30.00
Net PPE	-19.6%	2.00	2.00	2.00	3.00	3.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	-	6.00	-	7.00
Liabilities	-19.2%	7.00	8.00	8.00	9.00	11.00	13.00	14.00	14.00	15.00	27.00	27.00	10.00	7.00	15.00	-	13.00
Current Liabilities	-13.6%	6.00	7.00	7.00	6.00	8.00	10.00	9.00	9.00	8.00	14.00	13.00	2.00	1.00	7.00	0.00	4.00
Shareholder's Equity	-20.6%	30.00	38.00	46.00	55.00	63.00	76.00	77.00	90.00	103	110	124	23.00	35.00	47.00	58.00	29.00
Retained Earnings	-4.0%	-230	-221	-212	-202	-192	-178	-177	-164	-150	-142	-127	-5.94	-2.36	-88.00	0.00	-55.28
Additional Paid-In Capital	0.4%	261	260	258	257	256	255	256	255	254	252	251	11.00	7.00	135	0.00	1.00
Shares Outstanding	55.1%	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	-	1.00	1.00	-
Float	-	-	-	-	12.00	-	-	-	76.00	-	-	-	81.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	-20.4%	-8,746	-7,263	-10,200	-8,730	-14,170	-200	-14,113	-11,413	-18,374	-11,530	-14,058	-12,912	-10,300	-933	-7,537	-	-
Share Based Compensation	-12.1%	1,030	1,172	913	1,158	1,129	1,545	1,077	979	916	693	616	532	475	187	140	-	-
Cashflow From Investing	-100.1%	-7.00	9,500	7,646	17,249	17,328	1,913	22,831	13,977	-412	-16,621	-68,285	8,640	-1,442	-92,000	-247	-	-
Cashflow From Financing	-100.0%	-	141	-13.00	187	-39.00	-2,549	-13.00	-3.00	-	159	124,589	-314	196	93,921	13.00	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SRZN Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 5,247	$ 8,086
General and administrative	3,883	5,299
Restructuring	0	1,207
Total operating expenses	9,130	14,592
Loss from operations	(9,130)	(14,592)
Interest income	385	547
Other expense, net	(85)	(252)
Net loss	(8,830)	(14,297)
Unrealized gain on marketable securities, net of tax	0	191
Comprehensive loss	$ (8,830)	$ (14,106)
Net loss per share attributable to common stockholders, basic	$ (4.24)	$ (7.16)
Net loss per share attributable to common stockholders, diluted	$ (4.24)	$ (7.16)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	2,083	1,998
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	2,083	1,998

SRZN Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 27,290	$ 36,043
Accounts receivable	2,128	2,152
Prepaid expenses and other current assets	2,597	2,937
Total current assets	32,015	41,132
Property and equipment, net	1,584	1,969
Operating lease right-of-use assets	1,532	1,889
Restricted cash	688	688
Other assets	897	402
Total assets	36,716	46,080
Current liabilities:
Accounts payable	131	525
Accrued and other liabilities	3,485	4,126
Lease liabilities, current portion	2,563	2,497
Total current liabilities	6,179	7,148
Lease liabilities, noncurrent portion	223	882
Warrant liabilities	178	115
Total liabilities	6,580	8,145
Commitments and contingencies (Note 8)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000 shares authorized; no shares issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value, 500,000 shares authorized as of March 31,2024 and December 31, 2023; 2,107 and 2,063 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in-capital	260,661	259,630
Accumulated deficit	(230,525)	(221,695)
Total stockholders' equity	30,136	37,935
Total liabilities and stockholders’ equity	$ 36,716	$ 46,080

About Surrozen, Inc.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.

CEO	Mr. Craig C. Parker M.B.A.
WEBSITE	surrozen.com
INDUSTRY	Biotechnology
EMPLOYEES	74

Surrozen, Inc. Frequently Asked Questions

What is the ticker symbol for Surrozen, Inc.? What does SRZN stand for in stocks?

SRZN is the stock ticker symbol of Surrozen, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Surrozen, Inc. (SRZN)?

As of Thu May 16 2024, market cap of Surrozen, Inc. is 32.47 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SRZN stock?

You can check SRZN's fair value in chart for subscribers.

What is the fair value of SRZN stock?

You can check SRZN's fair value in chart for subscribers. The fair value of Surrozen, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Surrozen, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SRZN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Surrozen, Inc. a good stock to buy?

The fair value guage provides a quick view whether SRZN is over valued or under valued. Whether Surrozen, Inc. is cheap or expensive depends on the assumptions which impact Surrozen, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SRZN.

What is Surrozen, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, SRZN's PE ratio (Price to Earnings) is -0.86 and Price to Sales (PS) ratio is 2.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SRZN PE ratio will change depending on the future growth rate expectations of investors.